Latest Quarter
2026-03-31
Grace Therapeutics Inc (GRCE)
Revenue
$0.0
Net Income
-$1.2M
Operating Margin
N/A
Free Cash Flow
-$8.9M
Debt / Assets
4.1%
Values are in USD and rounded to the nearest whole number unless noted.
Swipe horizontally to view all columns.
| Income Statement (Quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 2,000 | 0 | 0 | 0 |
| Gross Profit | -2,000 | 0 | 0 | 0 |
| Operating Expenses | ||||
| R&D Expenses | 0 | 0 | 0 | 0 |
| SG&A Expenses | 308,589 | 2,723,678 | 2,733,670 | 2,133,000 |
| Operating Expenses | 3,008,000 | 3,360,346 | 3,527,272 | 3,090,000 |
| Operating Income | -3,010,000 | -3,360,346 | -3,527,272 | -3,090,000 |
| Interest Expense | 0 | 0 | 0 | 0 |
| Income Before Tax | -2,877,000 | -3,176,480 | -1,308,256 | -3,362,000 |
| Income Tax Expense | -1,700,000 | 0 | 0 | 0 |
| Net Income | -1,178,000 | -3,176,480 | -1,308,256 | -3,362,000 |
| Per Share | ||||
| EPS | -0.07 | -0.19 | -0.08 | -0.29 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Statement (Annual) | 2026-03-31 | 2025-03-31 | 2024-03-31 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 |
| Operating Expenses | |||
| R&D Expenses | 0 | 0 | 0 |
| SG&A Expenses | 8,665,000 | 10,198,051 | 6,644,000 |
| Operating Expenses | 11,077,000 | 23,752,730 | 12,852,000 |
| Operating Income | -11,077,000 | -23,752,730 | -12,852,000 |
| Interest Expense | 0 | 0 | 0 |
| Income Before Tax | -9,493,000 | -18,181,612 | -14,685,000 |
| Income Tax Expense | -1,700,000 | -4,555,727 | -1,832,000 |
| Net Income | -7,793,000 | -13,625,884 | -12,853,000 |
| Per Share | |||
| EPS | -0.47 | -1.13 | -1.73 |
| EPS Diluted | 0.00 | 0.00 | 0.00 |
| Balance Sheet (Quarterly) | 2026-03-31 | 2025-03-31 | 2024-03-31 |
|---|---|---|---|
| Assets | |||
| Cash and Cash Equivalents | 16,977,000 | 22,133,000 | 23,005,000 |
| Short Term Investments | 0 | 0 | 0 |
| Net Receivables | 20,000 | 126,000 | 722,000 |
| Inventory | 0 | 0 | 0 |
| Total Current Assets | 17,380,000 | 22,712,000 | 24,010,000 |
| Property Plant Equipment | 8,000 | 15,000 | 24,000 |
| Goodwill and Intangibles | 49,266,000 | 49,266,000 | 49,266,000 |
| Total Assets | 66,654,000 | 71,993,000 | 73,300,000 |
| Liabilities | |||
| Account Payables | 702,000 | 601,000 | 1,007,000 |
| Short Term Debt | 0 | 0 | 0 |
| Total Current Liabilities | 2,146,000 | 1,930,000 | 1,684,000 |
| Long Term Debt | 0 | 0 | 0 |
| Total Liabilities | 2,758,000 | 5,383,000 | 11,557,000 |
| Shareholders Equity | |||
| Retained Earnings | -228,480,000 | -220,687,000 | -211,119,000 |
| Total Shareholders Equity | 63,896,000 | 66,610,000 | 61,743,000 |
| Balance Sheet (Annual) | 2026-03-31 | 2025-03-31 | 2024-03-31 |
|---|---|---|---|
| Assets | |||
| Cash and Cash Equivalents | 16,977,000 | 22,133,000 | 23,005,000 |
| Short Term Investments | 0 | 0 | 0 |
| Net Receivables | 20,000 | 126,000 | 722,000 |
| Inventory | 0 | 0 | 0 |
| Total Current Assets | 17,380,000 | 22,712,000 | 24,010,000 |
| Property Plant Equipment | 8,000 | 15,000 | 24,000 |
| Goodwill and Intangibles | 49,266,000 | 49,266,000 | 49,266,000 |
| Total Assets | 66,654,000 | 71,993,000 | 73,300,000 |
| Liabilities | |||
| Account Payables | 702,000 | 601,000 | 1,007,000 |
| Short Term Debt | 0 | 0 | 0 |
| Total Current Liabilities | 2,146,000 | 1,930,000 | 1,684,000 |
| Long Term Debt | 0 | 0 | 0 |
| Total Liabilities | 2,758,000 | 5,383,000 | 11,557,000 |
| Shareholders Equity | |||
| Retained Earnings | -228,480,000 | -220,687,000 | -211,119,000 |
| Total Shareholders Equity | 63,896,000 | 66,610,000 | 61,743,000 |
| Cash Flow Statement (Quarterly) | 2026-03-31 | 2025-03-31 | 2024-03-31 |
|---|---|---|---|
| Operating Activities | |||
| Net Income | -7,793,000 | -9,568,000 | -12,853,000 |
| Depreciation & Amortization | 7,000 | 7,000 | 11,000 |
| Stock Based Compensation | 798,000 | 730,000 | 913,000 |
| Change in Working Capital | 719,000 | 342,000 | -1,280,000 |
| Operating Cash Flow | -8,869,000 | -14,904,000 | -12,333,000 |
| Investing Activities | |||
| Capital Expenditure | 0 | 0 | -22,000 |
| Investments | 0 | 0 | -22,000 |
| Investing Cash Flow | 0 | 0 | 104,000 |
| Financing Activities | |||
| Debt Repayment | 0 | 0 | 0 |
| Common Stock Issued/Repurchased | 3,713,000 | 14,999,000 | 7,338,000 |
| Dividends Paid | 0 | 0 | 0 |
| Financing Cash Flow | 3,713,000 | 14,032,000 | 7,359,000 |
| Summary | |||
| Free Cash Flow | -8,869,000 | -14,904,000 | -12,355,000 |
| Net Change in Cash | -5,156,000 | -872,000 | -4,870,000 |
| Cash Flow Statement (Annual) | 2026-03-31 | 2025-03-31 | 2024-03-31 |
|---|---|---|---|
| Operating Activities | |||
| Net Income | -7,793,000 | -9,568,000 | -12,853,000 |
| Depreciation & Amortization | 7,000 | 7,000 | 11,000 |
| Stock Based Compensation | 798,000 | 730,000 | 913,000 |
| Change in Working Capital | 719,000 | 342,000 | -1,280,000 |
| Operating Cash Flow | -8,869,000 | -14,904,000 | -12,333,000 |
| Investing Activities | |||
| Capital Expenditure | 0 | 0 | -22,000 |
| Investments | 0 | 0 | -22,000 |
| Investing Cash Flow | 0 | 0 | 104,000 |
| Financing Activities | |||
| Debt Repayment | 0 | 0 | 0 |
| Common Stock Issued/Repurchased | 3,713,000 | 14,999,000 | 7,338,000 |
| Dividends Paid | 0 | 0 | 0 |
| Financing Cash Flow | 3,713,000 | 14,032,000 | 7,359,000 |
| Summary | |||
| Free Cash Flow | -8,869,000 | -14,904,000 | -12,355,000 |
| Net Change in Cash | -5,156,000 | -872,000 | -4,870,000 |